RGX-314

GENETIC3 trials

Sponsors

REGENXBIO Inc., AbbVie

Conditions

Neovascular Age-related Macular DegenerationWet Age-related Macular DegenerationWet Macular Degeneration

Phase 1

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

CompletedNCT03066258

REGENXBIO Inc.Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration

Start: 2017-03-29End: 2021-06-17Updated: 2023-05-16

Phase 2

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Enrolling by invitationNCT03999801

AbbVieNeovascular Age-related Macular Degeneration, Wet Macular Degeneration

Start: 2019-05-31End: 2028-12-31Target: 865Updated: 2024-06-17

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

CompletedNCT04832724

AbbVieNeovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration, Wet Macular Degeneration

Start: 2021-02-22End: 2024-03-18Updated: 2024-09-05

Related Papers

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.

2024-03-2766 citations

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations